June 24, 2019
FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene
Vertex’s third medicine approved to treat the underlying cause of CF in eligible patients in this age range-